Rockies Chapter Meeting Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit: ACC Rockies Chapter Meeting 2025

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • TOP: Does Liberal Transfusion Post Surgery Improve Outcomes in Patients at High CV Risk?
    A liberal transfusion strategy following major vascular or general surgery did not significantly improve outcomes at 90 days post procedure in patients at high risk of a cardiac event when compared to a restrictive strategy, according to findings from the TOP trial presented at AHA 2025 and simultaneously published in JAMA.
  • New Trials Redefine Antithrombotic and Stroke Prevention Strategies in AFib
    Four major studies presented at AHA 2025 are reshaping strategies for managing atrial fibrillation (AFib) in complex clinical scenarios. OCEAN addresses whether ongoing anticoagulation is necessary after successful catheter ablation, offering fresh insights into stroke prevention and bleeding risk. ADAPT AF-DES and OPTIMA-AF explore optimal antithrombotic approaches after PCI, while CLOSURE-AF evaluates left atrial appendage […]
  • MAPLE-HCM: Treatment Benefit of Aficamten in Patients With Obstructive HCM
    Patients with obstructive hypertrophic cardiomyopathy (oHCM) treated with aficamten saw superior benefits in heart failure symptoms, exercise capacity, left ventricular outflow tract (LVOT) gradient and overall health status when compared to metoprolol, according to two analyses of the MAPLE-HCM trial presented at AHA 2025 and simultaneously published in JACC.
  • VESALIUS-CV: Evolocumab vs. Placebo in Patients Without Previous MI or Stroke
    Compared with placebo, PCSK9 inhibition with evolocumab reduced the risk of first cardiovascular events among patients with atherosclerosis or diabetes and without a previous myocardial infarction or stroke, based on findings from the VESALIUS-CV trial presented at AHA 2025 and simultaneously published in NEJM.
  • First-in-Human Trial Suggests CRISPR-Cas9 Therapy Targeting ANGPTL3 is Safe and Reduces LDL and Triglycerides
    A one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and reduced triglycerides by approximately 55%, based on findings from the CRISPR-Cas9 trial presented at AHA 2025 and simultaneously published in NEJM.